CYTO Stock: Price, Forecast, Financials & AI Analysis

Loading...

High

--

Open

--

VWAP

--

Vol

--

Mkt Cap

2.49M

Low

--

Amount

--

EV/EBITDA(TTM)

--

Total Shares

--

EV

814.65K

EV/OCF(TTM)

0.17

P/S(TTM)

3.01

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.

Show More

Events Timeline

(ET)

2025-12-19

09:10:00

Altamira Medica Receives China Approval for Bentrio Nasal Spray

2024-12-31 (ET)

2024-12-31

08:04:34

Altamira Therapeutics announces nanoparticle-based delivery of circular RNA

2024-12-20 (ET)

2024-12-20

07:09:35

Altamira Therapeutics announces transition from Nasdaq to OTC markets

2024-10-04 (ET)

2024-10-04

16:03:29

Altamira Therapeutics provides update on Nasdaq listing

2024-09-27 (ET)

2024-09-27

09:03:48

Altamira obtains extended ISO 13485 quality management system certification

2024-09-24 (ET)

2024-09-24

08:29:32

Altamira Therapeutics sees FY24 total cash needs $5.8M-$7M

2024-09-24

08:28:55

Altamira Therapeutics reports 1H EPS ($2.11) vs. ($21.55) last year

2024-09-16 (ET)

2024-09-16

08:35:56

Altamira announces expansion of Bentrio license, distribution agreement

2024-07-15 (ET)

2024-07-15

03:35:02

Altamira Therapeutics announces extension of Bentrio distribution agreement

News

an image of seekingalpha

14:12 PMseekingalpha

Cytophage Technologies Appoints New CFO James Kinley, Shares Down 5.26%

an image of Newsfilter

2024-12-20Newsfilter

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

an image of NASDAQ.COM

2024-10-15NASDAQ.COM

Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now

an image of Newsfilter

2024-09-24Newsfilter

Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript

an image of Newsfilter

2024-09-24Newsfilter

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

an image of SeekingAlpha

2024-09-17SeekingAlpha

Altamira Therapeutics prices up to $12M public offering (NASDAQ:CYTO)

0 Analyst Rating

Wall Street analysts forecast CYTO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

an image of No data

No data

Valuation Metrics

The current forward P/E ratio for Altamira Therapeutics Ltd (CYTO.O) is -0.23, compared to its 5-year average forward P/E of -0.52. For a more detailed relative valuation and DCF analysis to assess Altamira Therapeutics Ltd 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-0.52

Current PE

-0.23

Overvalued PE

0.03

Undervalued PE

-1.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-0.47

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.44

Undervalued EV/EBITDA

-1.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

0.05

Current PS

0.00

Overvalued PS

0.12

Undervalued PS

-0.03

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Altamira Therapeutics Ltd (CYTO) stock price today?

The current price of CYTO is 0 USD — it has increased 0 % in the last trading day.

What is Altamira Therapeutics Ltd (CYTO)'s business?

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.

What is the price predicton of CYTO Stock?

Wall Street analysts forecast CYTO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Altamira Therapeutics Ltd (CYTO)'s revenue for the last quarter?

Altamira Therapeutics Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Altamira Therapeutics Ltd (CYTO)'s earnings per share (EPS) for the last quarter?

Altamira Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

How many employees does Altamira Therapeutics Ltd (CYTO). have?

Altamira Therapeutics Ltd (CYTO) has 18 emplpoyees as of January 20 2026.

What is Altamira Therapeutics Ltd (CYTO) market cap?

Today CYTO has the market capitalization of 2.49M USD.